A Study of Oral LOXO-292 (Selpercatinib) in Pediatric Participants With Advanced Solid or Primary Central Nervous System (CNS) Tumors
Status: RECRUITING
Study type: INTERVENTIONAL
Conditions: Medullary Thyroid Cancer|Infantile Myofibromatosis|Infantile Fibrosarcoma|Papillary Thyroid Cancer|Soft Tissue Sarcoma
Interventions: DRUG: LOXO-292
Sponsor: Loxo Oncology, Inc.
Collaborators: Eli Lilly and Company